A cross-sectional study of health insurance database in Japan: Real-world surveillance for treatment of pediatric gout/ hyperuricemia with urate lowering agents

A cross-sectional study of health insurance database in Japan: Real-world surveillance for treatment of pediatric gout/ hyperuricemia with urate lowering agents - Real-world surveillance for treatment of pediatric gout/asymptomatic hyperuricemia with urate lowering agents

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036029

Enrollment

300

Registered

2019-02-27

Start date

2019-01-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gout and Hyperuricemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Subjects who are continuously identified in a JMDC Claim Database during the period between April 2016 and March 2017. If necessary, subjects who are identified between April 2012 and March 2016 would be analyzed as well. 2. Patients who have gout or asymptomatic hyperuricemia. (This criteria is not applied for denominator when calculating diagnosis and treatment rates for gout/hyperuricemia.) 3. Patients ages between 0 and 18 years old.

Exclusion criteria

Exclusion criteria: Patients who have malignancy. (This criteria is not applied for denominator when calculating diagnosis and treatment rates for gout/hyperuricemia.)

Design outcomes

Primary

Measure	Time frame
1. Prevalence rate and treatment rate with urate lowering agents for pediatric gout/asymptomatic hyperuricemia patients. 2. Patients' characteristics: patients with diagnosis and/or urate lowering treatment (ULT) in pediatric gout/asymptomatic hyperuricemia. 3. Number of ULT prescribed patients, average dosage, adherence and change of ULT agents 4. Incidence and prevalence of gouty arthritis	—

Countries

Japan

Contacts

Public ContactTomoko Torii, MSc.

Teijin Pharma Limited Medical Science Department

tpm-com@umin.ac.jp+81-3-3506-4140

Outcome results